Related Experiment Video
Updated: Jun 8, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Potential Value of Neoadjuvant Immunochemotherapy in Patients with Driver Gene-positive Non-small Cell Lung Cancer]
Zihan Wei1, Yu Zhou2, Xingxiang Pu2
1Department of Thoracic Oncology, Peking University People's Hospital, Beijing 100871, China.
Background:
The proportion of patients carrying driver gene mutations is notably high among individuals with non-small cell lung cancer (NSCLC) in China. However, the current neoadjuvant treatment strategies for these patients lack evident benefits. This study aims to investigate the efficacy and adverse reactions of neoadjuvant immunochemotherapy in patients with driver gene-positive NSCLC, thereby exploring its potential therapeutic value.
Methods:
A total of 50 patients from two centers were retrospectively collected to compare the efficacy and adverse reactions among driver gene-positive NSCLC patients after different treatments and further explore the response to neoadjuvant immunochemotherapy among different EGFR-sensitive subtypes.
Results:
A total of 50 patients from two centers were included in this study. Among the 40 patients from Peking University People's Hospital (PKUPH), 21 received neoadjuvant immunotherapy, with 57.1% showing partial response on imaging. The major pathological response (MPR) rate after neoadjuvant immunochemotherapy was 38.1%, and pathological complete response (pCR) was only observed in this group. No significant differences were noted in adverse events or their impact on surgical difficulty among different treatments. Additionally, 10 patients from Hunan Cancer Hospital (HNCA) were included to analyze the differences in efficiency among EGFR-sensitive subtypes under various neoadjuvant strategies. No significant radiological response differences were observed between neoadjuvant immunotherapy and targeted therapy. However, patients with the L858R mutation exhibited MPR and pCR only after receiving immunotherapy, surpassing targeted therapy outcomes, while no significant differences were found among 19del patients.
Conclusions:
Under the premise of not exacerbating adverse effects, neoadjuvant immunochemotherapy achieved superior rates of MPR and pCR, with long-term survival comparable to targeted therapy.
Insights
Neoadjuvant immunochemotherapy shows promise for driver gene-positive non-small cell lung cancer (NSCLC), achieving higher pathological response rates without increasing adverse events. This approach offers comparable long-term survival to targeted therapy for NSCLC patients.
Area of Science:
- Oncology
- Immunotherapy
- Thoracic Surgery
Context:
- Driver gene mutations are prevalent in Chinese non-small cell lung cancer (NSCLC) patients.
- Current neoadjuvant treatments offer limited benefits for these patients.
- Investigating novel neoadjuvant strategies is crucial for improving outcomes.
Purpose:
- To evaluate the efficacy and safety of neoadjuvant immunochemotherapy in driver gene-positive NSCLC.
- To compare outcomes across different EGFR-sensitive subtypes.
- To explore the therapeutic potential of neoadjuvant immunochemotherapy.
Summary:
- A retrospective study of 50 NSCLC patients compared neoadjuvant immunochemotherapy with other treatments.
- Neoadjuvant immunochemotherapy demonstrated higher rates of major pathological response (MPR) and pathological complete response (pCR).
- No significant increase in adverse events or surgical difficulty was observed.
Impact:
- Neoadjuvant immunochemotherapy offers superior pathological response rates in driver gene-positive NSCLC.
- This approach provides comparable long-term survival to targeted therapy.
- Findings support immunochemotherapy as a valuable neoadjuvant strategy for specific NSCLC patient populations.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
00:59Gene Therapy